The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bacterial Lysates on Respiratory Tract Microecology and Evaluation of the Efficacy of Prevention and Treatment of VAP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05270018
Recruitment Status : Unknown
Verified February 2022 by Sheng Wang MD PhD, Shanghai 10th People's Hospital.
Recruitment status was:  Recruiting
First Posted : March 8, 2022
Last Update Posted : March 8, 2022
Sponsor:
Information provided by (Responsible Party):
Sheng Wang MD PhD, Shanghai 10th People's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the effect of bacterial lysates on respiratory tract microecology in patients with mechanical ventilation and the efficacy of prevention and treatment of ventilator associated pneumonia.

Condition or disease Intervention/treatment Phase
Ventilators, Mechanical Drug: Bacterial Lysates Other: normal saline Not Applicable

Detailed Description:
After being informed about the study and potential risks, all patients giving written informed consent will undergo a one-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to Bacterial Lysates( 14mg, once a day) or placebo(once a day).
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Bacterial Lysates on Respiratory Tract Microecology in Patients With Mechanical Ventilation and Evaluation of the Efficacy of Prevention and Treatment of Ventilator-associated Pneumonia
Estimated Study Start Date : March 1, 2022
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : April 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Bacterial Lysate group
Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days
 Drug: Bacterial Lysates
14mg once a day
Other Name: Fan fusu
Placebo Comparator: Control group
Oral / gastric administration of normal saline once a day, 14.0ml each time
 Other: normal saline
14.0ml once a day


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. VAP incidence [ Time Frame: 2 weeks ]
    The incidence rate of ventilator associated pneumonia


Secondary Outcome Measures :
  1. Assessment of human immune status [ Time Frame: one week ]
    Immune status Assessment of IgG, IgA, and IgM levels Quantifications of IgG, IgA, and IgM levels were determined by Immunological Turbidity Kits

  2. drug resistant bacteria Incidence [ Time Frame: one week ]
    The incidence rate of drug resistant bacteria

  3. Composition of respiratory bacteria [ Time Frame: one week ]
    probiotics and pathogens via NGS analysis

  4. survival rate [ Time Frame: 28 days ]
    ICU in-hospital mortality and 28 day mortality


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients admitted to ICU for mechanical ventilation
  • The expected mechanical ventilation time is more than 72h
  • Sign the informed consent form when conscious and voluntary, and complete the questionnaire survey and follow-up as required; If it is unable to sign the informed consent form and complete the questionnaire survey and follow-up, the legal representative or guardian can act on behalf of it.

Exclusion Criteria:

  • Ventilator associated pneumonia is known and confirmed
  • Pregnant or lactating female
  • Allergic to the active ingredients of bacterial lysates or any excipients listed in the ingredients
  • Patients with autoimmune diseases
  • Patients with acute intestinal infection
  • Patients participating in other clinical studies at the same time
  • Patients considered unsuitable by other researchers to participate in this study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05270018


Contacts
Layout table for location contacts
Contact: Sheng Wang, MD, PhD 862166307174 wangsheng@tongji.edu.cn

Locations
Layout table for location information
China, Shanghai
Shanghai Tenth People's Hospital Recruiting
Shanghai, Shanghai, China, 200072
Contact: Qixing Wang, MSc    86-21-66307153    wangqixing1221@163.com   
Principal Investigator: Sheng Wang, MD, PhD         
Sponsors and Collaborators
Sheng Wang MD PhD
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sheng Wang MD PhD, Director, Shanghai 10th People's Hospital
ClinicalTrials.gov Identifier: NCT05270018    
Other Study ID Numbers: STPH-ICU-005
First Posted: March 8, 2022    Key Record Dates
Last Update Posted: March 8, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sheng Wang MD PhD, Shanghai 10th People's Hospital:
Ventilators; Bacterial Lysates; Microecology; pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Broncho-Vaxom
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs